PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 25, 2026Leukemia Research Reports0 citationsOpen Access

Evaluating the effectiveness of reduced-intensity conditioning regimens in acute myeloid leukemia patients after hematopoietic stem cell transplantation in Vietnam

View Full Paper
MHMan HuynhHHHuu Than HuynhTNThu Hanh Nguyen

Key Points

  • This study aims to evaluate the results of reduced-intensity conditioning regimens for patients with acute myeloid leukemia.
  • Retrospective observational study
  • Included 21 AML patients undergoing RIC from January 2021 to March 2024
  • Assessed recovery times and complications.
  • Median recovery time for neutropenia is 16 days and for thrombocytopenia is 26 days.
  • Complications included mucositis (95.2%), febrile episodes (85.7%), and CMV reactivation (83.3%).
  • 2-year disease-free survival is 61.4% and overall survival is 69.3%.

Abstract

Hematopoietic stem cell transplantation (HSCT) is an effective treatment for acute myeloid leukemia (AML) patients, leveraging cytotoxic conditioning regimens and graft-versus-leukemia effects. Reduced-intensity conditioning (RIC) regimens extend this therapy to elderly patients and those with severe comorbidities, minimizing toxicity while maintaining efficacy. The study aims to determine the result of reduced-intensity conditioning regimens for acute myeloid leukemia patients at Blood Transfusion Hematology Hospital, Vietnam. The retrospective observational study included 21 AML patients who underwent RIC from January 2021 to March 2024. Median recovery times for neutropenia and thrombocytopenia were 16 and 26 days, respectively. Complications included mucositis (95.2%), febrile episodes (85.7%), CMV reactivation (83.3%), acute GVHD (23.8%), and chronic GVHD (14.3%). The 2-year disease-free survival (DFS) and overall survival (OS) rates were 61.4% and 69.3%, respectively. Reduced-intensity conditioning regimens are a safe and effective treatment option for elderly AML patients with comorbidities.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Huynh et al. (2026) studied this question.

synapsesocial.com/papers/69ec59c688ba6daa22dab807https://doi.org/10.1016/j.lrr.2026.100590
Ask AI
Helpful
Bookmark
Share
View Full Paper